Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy

Journal of Clinical Oncology

Volumn 19, Issue 5, 2001, Pages 1468-1475

  Braun, S ^a   Cevatli, B S ^a   Assemi, C ^a   Janni, W ^a   Kentenich, C R M ^a   Schindlbeck, C ^a   Rjosk, D ^a   Hepp, F ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AXILLARY LYMPH NODE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; COBALT THERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

EID: 0035282163     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.5.1468     Document Type: Article

References (52)

1. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer
2. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up
3. Detection and clinical importance of micrometastic disease
4. Stopping metastases at their source
5. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy
6. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer
7. Breast cancer therapy: Exercising all our options
8. Significance of occult metastases: A study of breast cancer
9. Detection and significance of occult axillary node metastases in patients with invasive breast cancer
10. Axillary micro- and macrometastases in breast cancer
11. Importance of tumor cells in axillary node sinus margins (clandestine metastases) discovered by serial sectioning in operable breast carcinoma
12. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma
13. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance
14. Prognostic importance of occult axillary lymph node micrometastases from breast cancers
15. A preliminary report on the usefulness of monoclonal antibodies to CA 15- 3 and MCA in the detection of micrometastases in axillary lymph nodes draining primary breast carcinoma
16. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow up
17. Occult axillary lymph node metastases in "node-negative" breast carcinoma
18. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
19. Are breast cancer axillary node micrometastases worth detecting?
20. Prognostic significance of micrometastatic bone marrow involvement
21. Fifth International Conference on Adjuvant Therapy of Breast Cancer: St Gallen, March 1995 - International Consensus Panel on the Treatment of Primary Breast Cancer
22. Cytokeratin-immunoreactive cells of human lymph nodes and spleen in normal and pathological conditions: An immunocytochemical study
23. NCL-5D3: A new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunocytochemistry using paraffin-embedded tissue
24. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
25. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatant
26. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: The ISOBM TD5-workshop
27. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP-complexes)
28. Nonparametric estimation from incomplete observations
29. Regression models and life-tables
30. The dissemination of subcutaneously inoculated tumor cell suspensions
31. Findings from NSABP protocol No. B-04: Comparison of radical mastectomy with alternative treatments - II. The clinical and biologic significance of medial-central breast cancers
32. Prognosis based on primary breast carcinoma instead of pathological nodal status
33. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction
34. The detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
35. Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
36. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17- 1 monoclonal antibodies
37. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29: A comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG- 2
38. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
39. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
40. Cytoskeletal components of lymphoid organs: Synthesis of cytokeratin 8 and 18 and desmin in subpopulation of extrafollicular reticulum cells of human lymph nodes, tonsil and spleen
41. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
42. The immunocytochemical detection of axillary micrometastases in breast cancer
43. Standardisation of the immunocytochemical detection of cancer cells in bone marrow and blood: I. Establishment of objective criteria for the evaluation of immunostained cells
44. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
45. Detection of genetic alterations in micrometastatic cells in bone marrow of cancer patients by fluorescence in situ hybridization
46. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
47. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
48. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
49. Immunocytochemical monitoring of micrometastatic disease: Reduction of prostate cancer cells in bone marrow by androgen deprivation
50. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours
51. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow